非类固醇抗炎药物对骨关节炎的过程的影响
S Rashad1, P Revell, A Hemingway
1West Middlesex University Hospital.
Lancet (London, England)
|September 2, 1989
概括
非类固醇抗炎药物 (NSAIDs) 可能通过减少血液流动,使骨关节炎恶化. 强效的NSAIDs如印米他辛加速了关节骨关节炎患者的关节空间损失.
科学领域:
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 骨关节炎 (OA) 是一种退行性关节疾病,其特征是软骨的破坏.
- 非类固醇抗炎药物 (NSAIDs) 通常用于管理OA疼痛.
- 该假设表明,NSAIDs可能通过抑制血管扩展性前列腺素来加速OA的进展,从而减少关节输液.
研究的目的:
- 调查NSAID是否可以加速骨关节炎的进展.
- 确定抑制前列腺素合成对关节输液和OA进展的影响.
- 在关节骨关节炎患者中,比较一种强的 (印米他辛) 与一种弱的 (阿扎普罗帕) 前列腺素合成抑制剂的作用.
主要方法:
- 对105名骨关节炎患者进行前性研究,这些患者正在等待关节整形手术.
- 用印梅他辛 (强抑制剂) 或阿扎普罗帕 (弱抑制剂) 治疗的患者.
- 对切除的股骨头的疼痛,放射性关节空间和组织病理状况的监测.
主要成果:
- 两组治疗都在关节塑性术时达到类似的病理生理学终点.
- 与相反的部相比,印梅他辛组在受影响的部中显示出更快的关节空间损失.
- 阿扎普罗帕松组,具有较高的突血管扩展性前列腺素,经历了较慢的进展,并且需要更长时间才能达到终点.
结论:
- 强烈抑制前列腺素合成可能对治疗关节骨关节炎有害.
- 强烈抑制前列腺素合成的NSAIDs可能通过减少关节输液来加速OA的进展.
- 较弱的前列腺素合成抑制剂可能更适合关节OA管理.
相关概念视频
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...